This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Soleno Therapeutics Securities Fraud Lawsuit
Business class action

Soleno Therapeutics Securities Fraud Lawsuit

Analysis based on 9 articles · First reported Apr 01, 2026 · Last updated Apr 06, 2026

Sentiment
-60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against MiNK Therapeutics for alleged securities fraud has negatively impacted its stock price, which declined over 26% following revelations of issues with its DCCR clinical trial program. This event highlights the risks associated with pharmaceutical companies' clinical trial disclosures and can lead to increased scrutiny from investors and regulatory bodies in the biotechnology and pharmaceutical sectors.

Pharmaceuticals Legal Services
Event Summary

A securities fraud class action lawsuit has been filed against MiNK Therapeutics by the City of Pontiac Police and Fire Retirement System, alleging that MiNK Therapeutics made materially false and misleading statements and omissions regarding its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR). The lawsuit claims that MiNK Therapeutics downplayed safety concerns, including excess fluid retention, and misrepresented the commercial viability of DCCR. These allegations came to light after a report by Scorpion Capital on August 15, 2025, caused disruption in DCCR's launch trajectory and concerns within the Prader-Willi syndrome community. Following the report and MiNK Therapeutics' financial results on November 4, 2025, the company's stock price declined over 26%. Kessler Topaz Meltzer & Check is informing investors about the lawsuit and the May 5, 2026, deadline to seek lead plaintiff status.

Entities Involved
stock
MiNK Therapeutics
MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.
Importance 100.0 Sentiment -70.0
priv
Scorpion Capital
Scorpion Capital issued a report on August 15, 2025, which purportedly caused a disruption in DCCR's launch trajectory and revealed significant issues with MiNK Therapeutics' Phase 3 clinical trial program.
Importance 60.0 Sentiment 20.0
per
Jonathan Naji
Importance 0.0 Sentiment 0.0
priv
Kessler Topaz Meltzer & Check
Importance 0.0 Sentiment 0.0
Relationships
MiNK Therapeutics related ↔ Scorpion Capital
Jonathan Naji attorney ↔ Kessler Topaz Meltzer & Check Jonathan Naji is an attorney at the law firm Kessler Topaz Meltzer & Check, serving as a public contact for investors in
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.